A paradigm showing that both GLP-1 and NMDA receptors at caveolae sites may be promising and crucial targets for the treatment of cognitive dysfunctions has been presented here, which may also be able to modify the progression of Alzheimer’s disease. The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.